Combination studies of platinum(II)-based metallointercalators with buthionine-S,R-sulfoximine, 3-bromopyruvate, cisplatin or carboplatin

K. Benjamin Garbutcheon-Singh, Benjamin W. J. Harper, Simon Myers, Janice R. Aldrich-Wright

    Research output: Contribution to journalArticlepeer-review

    Abstract

    With current chemotherapeutic treatment regimes often limited by adverse side effects, the synergistic combination of complexes with anticancer activity appears to offer a promising strategy for effective cancer treatment. This work investigates the anti-proliferative activity using a combination therapy approach where metallointercalators of the type [Pt(IL)(AL)]2+ (where IL is the intercalating ligand and AL is the ancillary ligand) are used in combination with currently approved anticancer drugs cisplatin and carboplatin and organic molecules buthionine-S,R-sulfoximine and 3-bromopyruvate. Synergistic relationships were observed, indicating a potential to decrease dose-dependent toxicity and improve therapeutic efficacy.
    Original languageEnglish
    Pages (from-to)126-131
    Number of pages6
    JournalMetallomics
    Volume6
    Issue number1
    DOIs
    Publication statusPublished - 2014

    Fingerprint

    Dive into the research topics of 'Combination studies of platinum(II)-based metallointercalators with buthionine-S,R-sulfoximine, 3-bromopyruvate, cisplatin or carboplatin'. Together they form a unique fingerprint.

    Cite this